<DOC>
	<DOCNO>NCT00623766</DOCNO>
	<brief_summary>To assess response melanoma brain metastasis ipilimumab treatment maintain acceptable tolerability .</brief_summary>
	<brief_title>Evaluation Tumor Response Ipilimumab Treatment Melanoma With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Fludrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key inclusion criterion Histologically confirm malignant melanoma At least 1 measurable index brain metastasis &gt; 0.5 cm large 3 cm diameter previously irradiate , and/or 2 measurable lesion &gt; 0.3 cm visible contrast magnetic resonance Index brain lesion must resolve consequence prior therapy could confound attribution tumor response include edema hemorrhage Participants ipilimumab monotherapy arm ( include first 21 enrolled Stage 1 ) free neurologic symptom relate metastatic brain lesion must require received systemic corticosteroid therapy 10 day prior begin ipilimumab therapy Eastern Cooperative Oncology Group performance status 0 1 Required value initial laboratory test : White blood cell count ≥2000/μL Absolute neutrophil count ≥1000/μL Platelets ≥100*10^3/μL Hemoglobin level ≥9 g/dL ( may transfuse ) Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) level ≤2.5*ULN participant without liver metastasis AST/ALT level ≤5*ULN liver metastasis Bilirubin level ≤2*ULN ( except participant Gilbert 's Syndrome , must total bilirubin level less 3.0 mg/dL ) Age 16 year old Males female Women childbearing potential ( WOBP ) must use adequate method contraception avoid pregnancy throughout study ( 26 week last dose investigational product ) manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Key exclusion criterion History carcinomatous meningitis , prior stereotactic highly conformal radiotherapy and/or whole brain irradiation within 14 day first dose ipilimumab , document history autoimmune disease Prior stereotactic highly conformal radiotherapy and/or whole brain irradiation within 14 day prior start ipilimumab dosing study . Note stereotactic radiotherapy field must include brain index lesion lesion must detect confirm active progressing receive whole brain irradiation .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>